All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

teicoplanin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
glycopeptide antibacterials (Actinoplanes strains)	2998	61036-62-2

Description:

Molecule	Description
Synonyms: teicoplanin Antibiotic 8327A Antibiotic MDL 507 targocid targosid teichomycin	Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. Molecular weight: Formula: None CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
0.40	g	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	221.98	30.92	86	5179	42672	90580510
Thrombocytopenia	97.10	30.92	87	5178	208638	90414544
Multiple organ dysfunction syndrome	91.16	30.92	54	5211	68282	90554900
Stenotrophomonas infection	83.40	30.92	21	5244	2508	90620674
Septic shock	83.25	30.92	55	5210	84105	90539077
Acinetobacter infection	83.04	30.92	20	5245	1988	90621194
Pyrexia	79.26	30.92	139	5126	660346	89962836
Anaphylactic reaction	78.90	30.92	54	5211	87470	90535712
Neutropenia	76.64	30.92	79	5186	224825	90398357
Disseminated mucormycosis	62.58	30.92	13	5252	658	90622524
Renal impairment	59.20	30.92	49	5216	105372	90517810
Febrile neutropenia	58.22	30.92	58	5207	158291	90464891
Rash maculo-papular	56.27	30.92	33	5232	40900	90582282
Enterococcal infection	54.98	30.92	21	5244	9970	90613212
Toxic epidermal necrolysis	54.91	30.92	30	5235	32498	90590684
Drug resistance	53.95	30.92	29	5236	30420	90592762
Sepsis	52.09	30.92	58	5207	179756	90443426
Haemodynamic instability	51.69	30.92	21	5244	11718	90611464
Mental status changes postoperative	50.98	30.92	9	5256	189	90622993
Fungaemia	50.39	30.92	15	5250	3335	90619847
Confusion postoperative	48.85	30.92	9	5256	242	90622940
Mucormycosis	48.44	30.92	15	5250	3806	90619376
Pathogen resistance	48.06	30.92	18	5247	8097	90615085
Off label use	46.86	30.92	155	5110	1102097	89521085
Gastrointestinal mucormycosis	46.84	30.92	9	5256	305	90622877
Stevens-Johnson syndrome	46.58	30.92	26	5239	29350	90593832
Acute generalised exanthematous pustulosis	45.31	30.92	20	5245	13683	90609499
Tonsillitis bacterial	45.23	30.92	8	5257	170	90623012
Eosinophilia	44.55	30.92	25	5240	28508	90594674
Klebsiella infection	43.90	30.92	18	5247	10279	90612903
Cross sensitivity reaction	43.87	30.92	13	5252	2844	90620338
Morganella infection	43.57	30.92	10	5255	806	90622376
Haemostasis	39.09	30.92	8	5257	376	90622806
Bronchopulmonary aspergillosis	38.86	30.92	17	5248	11381	90611801
Pancytopenia	38.65	30.92	41	5224	120222	90502960
Graft versus host disease in liver	36.79	30.92	9	5256	954	90622228
Neutropenic sepsis	34.17	30.92	18	5247	18112	90605070
Rash macular	32.87	30.92	21	5244	30259	90592923
Fungal sepsis	32.59	30.92	9	5256	1532	90621650
Headache	31.57	30.92	6	5259	862740	89760442
Wound haemorrhage	31.13	30.92	10	5255	2857	90620325

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	187.04	23.62	108	7579	41967	42571681
Pyrexia	150.66	23.62	260	7427	393782	42219866
Multiple organ dysfunction syndrome	102.94	23.62	106	7581	96929	42516719
Anal inflammation	95.53	23.62	29	7658	2200	42611448
Cross sensitivity reaction	94.66	23.62	27	7660	1648	42612000
SARS-CoV-2 test negative	88.69	23.62	26	7661	1749	42611899
Thrombocytopenia	75.39	23.62	128	7559	190151	42423497
Neutropenia	72.29	23.62	129	7558	199302	42414346
Eosinophilia	69.13	23.62	53	7634	32846	42580802
Septic shock	66.12	23.62	82	7605	91590	42522058
Accident	65.25	23.62	29	7658	6474	42607174
Venoocclusive disease	64.92	23.62	25	7662	3890	42609758
Foetal cardiac arrest	64.90	23.62	10	7677	21	42613627
Rash maculo-papular	63.01	23.62	53	7634	37450	42576198
Fatigue	60.15	23.62	5	7682	435636	42178012
Geotrichum infection	54.74	23.62	14	7673	563	42613085
Systemic candida	54.26	23.62	24	7663	5295	42608353
Febrile neutropenia	53.49	23.62	109	7578	185594	42428054
Body temperature increased	49.92	23.62	36	7651	20322	42593326
Systemic mycosis	45.94	23.62	17	7670	2370	42611278
Drug resistance	44.77	23.62	42	7645	34206	42579442
Haemorrhoids	43.68	23.62	31	7656	17066	42596582
Haemophagocytic lymphohistiocytosis	41.91	23.62	31	7656	18191	42595457
Cytomegalovirus infection	41.04	23.62	39	7648	32267	42581381
Stevens-Johnson syndrome	38.59	23.62	32	7655	22146	42591502
Hyphaema	37.97	23.62	11	7676	709	42612939
Death	37.81	23.62	19	7668	471166	42142482
Fungal infection	37.57	23.62	30	7657	19692	42593956
Sepsis	37.50	23.62	99	7588	199235	42414413
Pathogen resistance	36.97	23.62	24	7663	11426	42602222
Dizziness	33.95	23.62	3	7684	249251	42364397
Drug ineffective	32.57	23.62	209	7478	629988	41983660
Respiratory gas exchange disorder	32.16	23.62	9	7678	512	42613136
Cellulitis	31.99	23.62	47	7640	61538	42552110
Toxic skin eruption	30.77	23.62	23	7664	13707	42599941
Encephalitis brain stem	30.73	23.62	7	7680	171	42613477
C-reactive protein increased	28.07	23.62	45	7642	63515	42550133
Acute generalised exanthematous pustulosis	27.70	23.62	18	7669	8577	42605071
Acute kidney injury	27.66	23.62	135	7552	367202	42246446
Brain abscess	27.34	23.62	14	7673	4270	42609378
Thrombotic microangiopathy	27.12	23.62	22	7665	14760	42598888
Infective aneurysm	25.87	23.62	9	7678	1050	42612598
Pancytopenia	25.77	23.62	62	7625	117681	42495967
Hepatotoxicity	25.72	23.62	27	7660	25140	42588508
Mast cell degranulation present	24.71	23.62	5	7682	68	42613580
Weight decreased	24.63	23.62	4	7683	207944	42405704
Renal impairment	24.08	23.62	58	7629	110170	42503478

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	393.00	23.86	192	12816	81903	110494388
Pyrexia	233.47	23.86	394	12614	897871	109678420
Multiple organ dysfunction syndrome	194.31	23.86	153	12855	151557	110424734
Thrombocytopenia	174.99	23.86	210	12798	348675	110227616
Neutropenia	155.23	23.86	205	12803	374415	110201876
Septic shock	150.16	23.86	134	12874	157394	110418897
Cross sensitivity reaction	125.21	23.86	40	12968	5527	110570764
Rash maculo-papular	119.69	23.86	86	12922	74136	110502155
Eosinophilia	119.15	23.86	78	12930	57858	110518433
Febrile neutropenia	112.48	23.86	161	12847	316606	110259685
Acinetobacter infection	111.45	23.86	33	12975	3540	110572751
Anal inflammation	99.94	23.86	28	12980	2468	110573823
Sepsis	91.60	23.86	149	12859	327197	110249094
SARS-CoV-2 test negative	90.08	23.86	25	12983	2128	110574163
Drug resistance	87.85	23.86	64	12944	56310	110519981
Fatigue	86.27	23.86	19	12989	1215939	109360352
Anaphylactic reaction	85.39	23.86	85	12923	114215	110462076
Geotrichum infection	79.03	23.86	20	12988	1192	110575099
Stenotrophomonas infection	76.45	23.86	28	12980	5830	110570461
Systemic mycosis	71.89	23.86	24	12984	3805	110572486
Toxic skin eruption	71.53	23.86	43	12965	27472	110548819
Stevens-Johnson syndrome	70.26	23.86	52	12956	46849	110529442
Acute generalised exanthematous pustulosis	67.28	23.86	38	12970	21626	110554665
Renal impairment	65.63	23.86	95	12913	188350	110387941
Venoocclusive disease	63.54	23.86	25	12983	6325	110569966
Enterococcal infection	61.30	23.86	35	12973	20331	110555960
Pathogen resistance	60.35	23.86	33	12975	17639	110558652
Drug ineffective	59.60	23.86	342	12666	1520198	109056093
Accident	59.53	23.86	28	12980	10924	110565367
Disseminated mucormycosis	59.44	23.86	18	12990	2084	110574207
Haemophagocytic lymphohistiocytosis	58.85	23.86	40	12968	31519	110544772
Acute kidney injury	58.80	23.86	186	12822	635244	109941047
Toxic epidermal necrolysis	57.45	23.86	50	12958	56677	110519614
Pancytopenia	56.64	23.86	94	12914	209519	110366772
Systemic candida	55.76	23.86	26	12982	9948	110566343
Dizziness	53.43	23.86	9	12999	698184	109878107
Off label use	52.06	23.86	327	12681	1499858	109076433
Fungal infection	51.89	23.86	45	12963	50761	110525530
Fungaemia	50.69	23.86	21	12987	6065	110570226
Cytomegalovirus infection	49.20	23.86	45	12963	54399	110521892
Headache	43.44	23.86	25	12983	882352	109693939
Haemodynamic instability	42.65	23.86	29	12979	22859	110553432
Klebsiella infection	41.26	23.86	27	12981	19982	110556309
Weight decreased	40.67	23.86	4	13004	468053	110108238
Cellulitis	40.20	23.86	61	12947	125955	110450336
Fall	39.61	23.86	11	12997	603471	109972820
Mucormycosis	39.51	23.86	21	12987	10607	110565684
Cholestasis	39.22	23.86	43	12965	64475	110511816
Mental status changes postoperative	38.31	23.86	8	13000	201	110576090
Platelet count decreased	38.24	23.86	84	12924	230359	110345932
Hyphaema	37.94	23.86	11	12997	1096	110575195
Joint swelling	37.91	23.86	4	13004	442841	110133450
Haemorrhoids	37.24	23.86	32	12976	35640	110540651
Tonsillitis bacterial	36.98	23.86	8	13000	239	110576052
Bronchopulmonary aspergillosis	35.76	23.86	29	12979	29834	110546457
Dermatitis exfoliative	35.49	23.86	20	12988	11327	110564964
Candida infection	34.53	23.86	35	12973	47974	110528317
Drug intolerance	33.97	23.86	4	13004	406508	110169783
Confusion postoperative	33.80	23.86	8	13000	360	110575931
Gastrointestinal mucormycosis	32.83	23.86	9	12999	732	110575559
Brain abscess	32.80	23.86	16	12992	6758	110569533
Nasopharyngitis	32.65	23.86	4	13004	394357	110181934
Abdominal discomfort	32.60	23.86	4	13004	393854	110182437
Alopecia	31.98	23.86	3	13005	364750	110211541
Fusarium infection	31.60	23.86	12	12996	2759	110573532
Morganella infection	31.38	23.86	10	12998	1369	110574922
Hepatotoxicity	31.37	23.86	38	12970	63362	110512929
C-reactive protein increased	31.25	23.86	75	12933	217844	110358447
Respiratory gas exchange disorder	31.11	23.86	9	12999	889	110575402
Hyperbilirubinaemia	30.97	23.86	27	12981	30644	110545647
Body temperature increased	30.74	23.86	35	12973	54678	110521613
Posterior reversible encephalopathy syndrome	30.61	23.86	28	12980	33833	110542458
Haemostasis	30.52	23.86	8	13000	548	110575743
Thrombotic microangiopathy	30.12	23.86	26	12982	29123	110547168
Shock	29.63	23.86	34	12974	53554	110522737
Graft versus host disease in liver	29.29	23.86	11	12997	2454	110573837
Encephalitis brain stem	28.96	23.86	7	13001	345	110575946
Agranulocytosis	28.92	23.86	36	12972	61724	110514567
Arthralgia	27.22	23.86	31	12977	779601	109796690
Graft versus host disease in skin	27.04	23.86	15	12993	8239	110568052
Device related infection	26.95	23.86	28	12980	39491	110536800
Staphylococcal infection	26.89	23.86	37	12971	69907	110506384
Mast cell degranulation present	26.85	23.86	5	13003	68	110576223
Asthenia	26.76	23.86	25	12983	688974	109887317
Pain in extremity	26.62	23.86	12	12996	487106	110089185
Infective aneurysm	26.62	23.86	9	12999	1483	110574808
Dyspnoea	26.32	23.86	57	12951	1106815	109469476
Acute myeloid leukaemia	25.98	23.86	27	12981	38083	110538208
Graft versus host disease in gastrointestinal tract	25.88	23.86	15	12993	8953	110567338
Cytokine release syndrome	25.25	23.86	36	12972	70270	110506021
Rash erythematous	25.23	23.86	39	12969	81793	110494498
Liver abscess	25.18	23.86	14	12994	7725	110568566
Weight increased	25.11	23.86	9	12999	419635	110156656
Depression	24.44	23.86	4	13004	317331	110258960
Cardiac arrest	24.31	23.86	64	12944	196689	110379602

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01XA02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Glycopeptide antibacterials
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
CHEBI has role	CHEBI:33281	antimicrobial agent
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:36047	antibacterial drug

Related Drugs by ATC class:

J01XA Glycopeptide antibacterials 4 drugs

dalbavancinoritavancintelavancinvancomycin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Staphylococcal infectious disease	indication	56038003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4025272	VUID
N0000171799	NUI
D02142	KEGG_DRUG
4025272	VANDF
C0145106	UMLSCUI
CHEBI:29687	CHEBI
CHEMBL4297166	ChEMBL_ID
D017334	MESH_DESCRIPTOR_UI
DB06149	DRUGBANK_ID
10924	IUPHAR_LIGAND_ID
5155	INN_ID
4U3D3YY81M	UNII
133065662	PUBCHEM_CID
196469	RXNORM
003765	NDDF
387529008	SNOMEDCT_US
96014005	SNOMEDCT_US

Pharmaceutical products:

None